Icon (ICLRN) AI Stock Analysis

Icon

(BMV:ICLRN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Record bookings and backlogRecord bookings and sustained book-to-bill above 1.3x indicate strong sponsor demand and support backlog conversion into future revenue. Continued wins across large pharma, midsized companies, and biotech can reinforce ICON’s market position and improve medium-term growth visibility.

Negative Factors

Persistent revenue pressureRecent revenue contraction shows that strong bookings have not yet translated into comparable top-line growth. The decline, including the effect of the Symphony divestiture, raises execution risk around backlog conversion and leaves near-term growth dependent on renewed demand and delivery.

Icon (ICLRN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 16.31B
Dividend Yield: ―
Average Volume (3M): 348
Price to Earnings (P/E): 36.1
Beta (1Y): 0.16
Revenue Growth: -9.68%
EPS Growth: 19.93%
Country: Mexico
Employees: 40,200
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Icon Business Overview & Revenue Model

Company Description

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, ma...

Icon Earnings Call Summary

Earnings Call Date:Oct 26, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Jun 22, 2026

Earnings Call SentimentPositive

The call was strongly positive overall. Commercial momentum, record net bookings, sustained book-to-bill performance, margin expansion, cost discipline, cash generation, technology productivity gains, and constructive demand outweighed the year-over-year revenue decline, pass-through volatility, foreign exchange headwind, and expected fourth-quarter SG&A increase.

Positive Updates

Adjusted EBITDA and EPS Growth

Adjusted EBITDA increased 3% sequentially to $337 million, while adjusted EBITDA margin expanded by 70 basis points to 16.6%. Adjusted EPS was $2.66, an increase of 4% compared with Q2.

Negative Updates

Revenue Decline

Q3 revenue was just over $2 billion, representing a year-over-year decrease of 2.9%, or 2.5% on a constant-currency basis. Revenue also decreased 1.9% sequentially, primarily reflecting the divestiture of Symphony.

Company Guidance

For 2026, updated full year guidance reflects higher pass through activity, supporting an increase in the revenue outlook to the high end of the prior range, or about $150 million at the midpoint from where it was before; full year EBITDA margin is expected to be somewhere in the region of 16% to 16.5%, the adjusted effective tax rate approximately 17%, and Q4 SG&A should increase. Pass throughs are currently somewhere in the low thirties, approaching 1 third of revenues approximately, with somewhere in or around that range a reasonable place to think about for next year. The company is not guiding today for 2027, but said it is certainly viable to think about mid single digit revenue expansion next year and maybe higher single digit expansion on earnings, with good execution, meaningful earnings progression, and even at the midpoint another dozen cents or so of earnings expansion quarter over quarter.

Icon Risk Analysis

Icon disclosed 66 risk factors in its most recent earnings report. Icon reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.We have concluded that our internal control over financial reporting and our disclosure controls and procedures were not effective as of December 31, 2025 due to material weaknesses, which has adversely affected our ability to report our financial results in a timely and accurate manner and could have a material adverse impact on our business and financial condition.Q4, 2025

2.If we fail to maintain proper and effective internal controls, our business and financial condition could be materially adversely impacted.Q4, 2025

3.Due to inherent limitations, there can be no assurance that our system of disclosure and internal controls and procedures will be successful in preventing all errors, theft and fraud, or in informing management of all material information in a timely manner.Q4, 2025

Icon Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:ICLRN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDP	84Outperform	$18.24B	35.51	99.76%	―	20.35%	25.24%
TMO	77Outperform	$257.71B	36.70	13.31%	0.26%	8.27%	9.59%
LH	75Outperform	$29.31B	29.45	11.54%	0.80%	6.02%	19.63%
IQV	74Outperform	$44.06B	32.13	21.82%	―	8.88%	13.11%
CRL	58Neutral	$17.16B	-74.26	-7.72%	―	-0.74%	-268.79%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:ICLRN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:ICLRN	Icon Plc	2914.91	-99.13	-3.29%
CRL	Charles River Laboratories Intl	359.41	180.55	100.94%
LH	Labcorp Holdings Inc.	361.39	106.13	41.58%
TMO	Thermo Fisher Scientific	697.00	134.10	23.82%
IQV	IQVIA Holdings	267.33	53.45	24.99%
MEDP	Medpace Holdings Inc	652.01	57.99	9.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Icon AI Stock Analysis